Ignite Creation Date:
2024-05-06 @ 8:09 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06277024
Status:
RECRUITING
Last Update Posted:
2024-02-26
First Post:
2024-02-04
Brief Title:
A Study on the Safety and Efficacy of the Combination of Candenizumab Lenvatinib and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
Sponsor:
Fujian Medical University
Organization:
Fujian Medical University
Organization Data
Organization:
Fujian Medical University
Class:
OTHER
Study ID:
FUGES-32
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fujian Medical University
Lead Sponsor Class:
OTHER
Responsible Party:
Chang-Ming Huang Prof
Responsible Party Title:
chief physician
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Fujian Medical University
Old Name:
None
Old Organization:
None